ClinicalTrials.gg
CompletedNCT03879408Updated Dec 5, 2022Results posted

Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study

A Phase 2 interventional study of 440 mg naproxen sodium with 1000 mg acetaminophen and 220 mg naproxen sodium with 650 mg acetaminophen in Pain, sponsored by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division. Completed at 1 site in United States. Open to participants aged 17 Years to 50 Years. Per ClinicalTrials.gov, last updated 2022-12-05.

Sponsored by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division (formerly part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
17 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing naproxen in Pain — 1 open to participants now, 2 under way, none of them phase 3. Naproxen · Pain.

Enrollment
6th of 25
290 · median 100
Started
2019
with 1 other
Phase 2
4 of 25
1 open now
Registered
15th of 25
by date
Lead sponsor
1 of 25
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division

Among the 25 studies testing naproxen in Pain, this one is the 6th largest by enrollment, is one of 2 that started in 2019, is one of 4 in phase 2, and was the 15th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

1 of the 25 studies testing naproxen in Pain is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About naproxen

Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 17 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing naproxen in Pain, or all of them as a file.
02

Study summary

Study assessing efficacy and safety of concomitantly dosed naproxen sodium with acetaminophen, compared with naproxen sodium, hydrocodone/acetaminophen and Placebo in a postoperative dental pain.

Read the detailed description

This is a randomized, double-blind, placebo- and active-controlled, parallel-group study to evaluate the analgesic efficacy and safety of concomitantly administered naproxen sodium 440 mg with acetaminophen 1000 mg and concomitantly administered naproxen sodium 220 mg with acetaminophen 650 mg, compared with a fixed combination of hydrocodone 10 mg/acetaminophen 650 mg, naproxen sodium 440 mg, and placebo over a twelve-hour period after surgical extraction of four third molars.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Analgesics
  • Dental Pain
  • Naproxen
  • Acetaminophen
  • Pain
04

Who can participate

Ages eligible
17 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males of females 17-50 years old
  2. Weigh 100 pounds or greater and have a (BMI) of 18.5 to 35 (inclusive) at screening
  3. Surgical removal of up to four third molars, of which, two must be mandibular impactions
  4. Meets requirements for post -surgical pain level
  5. Females of and males agree to requirements of study
  6. Have a negative urine drug screen at screening, and on day of surgical procedure

Exclusion criteria

Exclusion Criteria:

  1. Pregnant female, breastfeeding, trying to become pregnant or male with pregnant partner or partner currently trying to become pregnant
  2. Have known allergy or to naproxen or other NSAIDS, including aspirin, or to acetaminophen, tramadol, hydrocodone or other opioids
  3. Not able to swallow large tablets or capsules
  4. History of any condition (s) in investigator's opinion, may jeopardize subject safety, well-being and integrity of study
  5. Use analgesics 5 or more times per week
  6. History of chronic tranquilizer use, heavy drinking, substance abuse as judged by investigator site staff within last 5 years
  7. Use of drugs within 2 weeks of screening
  8. History of peptic ulcer disease or gastrointestinal bleeding in the last two years or hematologic bleeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
290 participants (actual)

Study arms

  • Experimental
    440 mg naproxen sodium with 1000 mg acetaminophen

    440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets

    Drug: 440 mg naproxen sodium with 1000 mg acetaminophen

  • Experimental
    220 mg naproxen sodium with 650 mg acetaminophen

    220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet

    Drug: 220 mg naproxen sodium with 650 mg acetaminophen

  • Active comparator
    10 mg hydrocodone + 650 mg acetaminophen

    10 mg hydrocodone + 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets

    Drug: 10 mg hydrocodone + 650 mg acetaminophen

  • Active comparator
    440 mg naproxen sodium

    440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets

    Drug: 440 mg naproxen sodium

  • Placebo comparator
    Placebo tablet

    Single dose of four placebo tablets

    Drug: Placebo tablet

Interventions

  • Drug440 mg naproxen sodium with 1000 mg acetaminophen

    Drug pages: Naproxen · Acetaminophen

    440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets

    Also known as: Naproxen Sodium with Acetaminophen - High Dose

  • Drug220 mg naproxen sodium with 650 mg acetaminophen

    Drug pages: Naproxen · Acetaminophen

    220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet

    Also known as: Naproxen Sodium with Acetaminophen - Low Dose

  • Drug10 mg hydrocodone + 650 mg acetaminophen

    Drug pages: Hydrocodone · Acetaminophen

    10 mg hydrocodone with 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets

    Also known as: Commercial Hydrocodone + Acetaminophen Tablet

  • 440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets

    Also known as: Naproxen sodium

  • DrugPlacebo tablet

    Single dose of four placebo tablets

06

What researchers measure

Primary outcomes

  1. Time-Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 6 Hours (SPID 0-6)

    Time-weighted sum of the pain intensity difference (SPID) score was measured using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain). The possible range of SPID for 0-6 hours was from -60 to 60. A higher value of SPID indicated greater pain relief. PID was the difference between baseline pain intensity and pain intensity at assessment. Time-weighted sum of the pain intensity difference scores were derived by first multiplying each PID score by the time from the previous time point and adding these time-weighted PID scores together over the intervals from 0 to 6 hours.

    Time frame: Baseline (0 hour) up to 6 hours post-dose

  2. Time-weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 12 Hours (SPID 0-12)

    Time-weighted sum of the pain intensity difference score was measured using a PI-NRS ranging from 0-10 (0 = no pain, 10 = very severe pain). The possible range of SPID for 0-12 hours was from -120 to 120. A higher value of SPID indicated greater pain relief. PID was the difference between baseline pain intensity and pain intensity at assessment (12 hours). Time-weighted sum of the pain intensity difference scores were derived by first multiplying each PID score by the time from the previous time point and adding these time-weighted PID scores together over the intervals from 0 to 12 hours.

    Time frame: Baseline (0 hour) up to 12 hours post-dose

Secondary outcomes

  1. Time-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 6 Hours (TOTPAR 0-6)

    Time-weighted total pain relief (TOTPAR) was measured using a Pain Relief Numerical Rating Scale (PR-NRS) ranging from 0-10 (0 = no relief, 10 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 60. Higher scores was indicative of more pain relief.

    Time frame: Baseline (0 hour) up to 6 hours post-dose

  2. Time-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 8 Hours (TOTPAR 0-8)

    TOTPAR was measured using a PR-NRS ranging from 0-10 (0 = no relief, 10 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 80. Higher scores was indicative of more pain relief.

    Time frame: Baseline (0 hour) up to 8 hours post-dose

  3. Time-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 12 Hours (TOTPAR 0-12)

    TOTPAR was measured using a PR-NRS ranging from 0-10 (0 = no relief, 10 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 120. Higher scores was indicative of more pain relief.

    Time frame: Baseline (0 hour) up to 12 hours post-dose

  4. Time-Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 8 Hours (SPID 0-8)

    Time-weighted sum of the pain intensity difference score was measured using a PI-NRS ranging from 0-10 (0 = no pain, 10 = very severe pain). The possible range of SPID for 0-8 hours was from -80 to 80. A higher value of SPID indicated greater pain relief. PID was the difference between baseline pain intensity and pain intensity at assessment (8 hours). Time-weighted sum of the pain intensity difference scores were derived by first multiplying each PID score by the time from the previous time point and adding these time-weighted PID scores together over the intervals from 0 to 8 hours.

    Time frame: Baseline (0 hour) up to 8 hours post-dose

  5. Pain Relief (PAR) Scores at Individual Timepoints

    Participants answered a question at individual time points: "how much relief do you have from your starting pain?" on a 11-point PR-NRS. Scale ranged from 0=no relief to 10=complete relief. Higher score indicated improvement in pain.

    Time frame: 0.25 hours, 0.5 hours, 0.75 hours, 1 hours, 1.25 hours, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, and 12 hours

  6. Pain Intensity Difference (PID) Scores at Individual Time Points

    Pain Intensity was self-reported over 12 hours, using a pain rating of 0-10 on the PI-NRS, with score ranged from 0-10 (0= no pain; 10 = worst imaginable pain). Pain intensity differences were calculated with respect to baseline at each time point after study drug administration.

    Time frame: 0.25 hours, 0.5 hours, 0.75 hours, 1 hours, 1.25 hours, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, and 12 hours

  7. Participant's Global Evaluation of Study Medication OR Overall Impression of Study Medication According to Participant's Global Evaluation

    Participants were asked to rate their overall impression of the study medication using the following scale: poor (0), fair (1), good (2), very good (3), and excellent (4) where higher score represented better outcome.

    Time frame: Up to 12 hours

07

Results

Posted Dec 5, 2022

Participant flow

Participant flow — Overall Study
MilestoneArm 1: PlaceboArm 2: Naproxen Sodium 440 mgArm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mgArm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mgArm 5: Hydrocodone 10 mg + Acetaminophen 650 mg
Started3569616362
Completed3365586261
Not completed24311
Withdrew: Lost to follow-up03210
Withdrew: Withdrawal by subject21101

Outcome measures

PrimaryTime-Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 6 Hours (SPID 0-6)

Time-weighted sum of the pain intensity difference (SPID) score was measured using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain). The possible range of SPID for 0-6 hours was from -60 to 60. A higher value of SPID indicated greater pain relief. PID was the difference between baseline pain intensity and pain intensity at assessment. Time-weighted sum of the pain intensity difference scores were derived by first multiplying each PID score by the time from the previous time point and adding these time-weighted PID scores together over the intervals from 0 to 6 hours.

Time frame:
Baseline (0 hour) up to 6 hours post-dose
Reported as:
Least squares mean · Units on a scale
Time-Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 6 Hours (SPID 0-6)
Units on a scaleArm 1: PlaceboArm 2: Naproxen Sodium 440 mgArm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mgArm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mgArm 5: Hydrocodone 10 mg + Acetaminophen 650 mg
Time-Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 6 Hours (SPID 0-6)2.36 ± 2.18125.59 ± 1.56230.28 ± 1.67733.77 ± 1.63323.60 ± 1.651
PrimaryTime-weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 12 Hours (SPID 0-12)

Time-weighted sum of the pain intensity difference score was measured using a PI-NRS ranging from 0-10 (0 = no pain, 10 = very severe pain). The possible range of SPID for 0-12 hours was from -120 to 120. A higher value of SPID indicated greater pain relief. PID was the difference between baseline pain intensity and pain intensity at assessment (12 hours). Time-weighted sum of the pain intensity difference scores were derived by first multiplying each PID score by the time from the previous time point and adding these time-weighted PID scores together over the intervals from 0 to 12 hours.

Time frame:
Baseline (0 hour) up to 12 hours post-dose
Reported as:
Least squares mean · Units on a scale
Time-weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 12 Hours (SPID 0-12)
Units on a scaleArm 1: PlaceboArm 2: Naproxen Sodium 440 mgArm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mgArm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mgArm 5: Hydrocodone 10 mg + Acetaminophen 650 mg
Time-weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 12 Hours (SPID 0-12)5.80 ± 4.66650.07 ± 3.34155.47 ± 3.58766.43 ± 3.49439.94 ± 3.533
SecondaryTime-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 6 Hours (TOTPAR 0-6)

Time-weighted total pain relief (TOTPAR) was measured using a Pain Relief Numerical Rating Scale (PR-NRS) ranging from 0-10 (0 = no relief, 10 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 60. Higher scores was indicative of more pain relief.

Time frame:
Baseline (0 hour) up to 6 hours post-dose
Reported as:
Least squares mean · Units on a scale
Time-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 6 Hours (TOTPAR 0-6)
Units on a scaleArm 1: PlaceboArm 2: Naproxen Sodium 440 mgArm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mgArm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mgArm 5: Hydrocodone 10 mg + Acetaminophen 650 mg
Time-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 6 Hours (TOTPAR 0-6)7.96 ± 2.58135.20 ± 1.84840.94 ± 1.98445.13 ± 1.93332.88 ± 1.954
SecondaryTime-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 8 Hours (TOTPAR 0-8)

TOTPAR was measured using a PR-NRS ranging from 0-10 (0 = no relief, 10 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 80. Higher scores was indicative of more pain relief.

Time frame:
Baseline (0 hour) up to 8 hours post-dose
Reported as:
Least squares mean · Units on a scale
Time-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 8 Hours (TOTPAR 0-8)
Units on a scaleArm 1: PlaceboArm 2: Naproxen Sodium 440 mgArm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mgArm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mgArm 5: Hydrocodone 10 mg + Acetaminophen 650 mg
Time-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 8 Hours (TOTPAR 0-8)11.12 ± 3.55447.19 ± 2.54554.37 ± 2.73260.78 ± 2.66241.61 ± 2.691
SecondaryTime-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 12 Hours (TOTPAR 0-12)

TOTPAR was measured using a PR-NRS ranging from 0-10 (0 = no relief, 10 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 120. Higher scores was indicative of more pain relief.

Time frame:
Baseline (0 hour) up to 12 hours post-dose
Reported as:
Least squares mean · Units on a scale
Time-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 12 Hours (TOTPAR 0-12)
Units on a scaleArm 1: PlaceboArm 2: Naproxen Sodium 440 mgArm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mgArm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mgArm 5: Hydrocodone 10 mg + Acetaminophen 650 mg
Time-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 12 Hours (TOTPAR 0-12)18.20 ± 5.59569.96 ± 4.00676.80 ± 4.30190.22 ± 4.19057.03 ± 4.237
SecondaryTime-Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 8 Hours (SPID 0-8)

Time-weighted sum of the pain intensity difference score was measured using a PI-NRS ranging from 0-10 (0 = no pain, 10 = very severe pain). The possible range of SPID for 0-8 hours was from -80 to 80. A higher value of SPID indicated greater pain relief. PID was the difference between baseline pain intensity and pain intensity at assessment (8 hours). Time-weighted sum of the pain intensity difference scores were derived by first multiplying each PID score by the time from the previous time point and adding these time-weighted PID scores together over the intervals from 0 to 8 hours.

Time frame:
Baseline (0 hour) up to 8 hours post-dose
Reported as:
Least squares mean · Units on a scale
Time-Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 8 Hours (SPID 0-8)
Units on a scaleArm 1: PlaceboArm 2: Naproxen Sodium 440 mgArm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mgArm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mgArm 5: Hydrocodone 10 mg + Acetaminophen 650 mg
Time-Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 8 Hours (SPID 0-8)3.24 ± 2.98134.11 ± 2.13439.98 ± 2.29145.27 ± 2.23229.58 ± 2.257
SecondaryPain Relief (PAR) Scores at Individual Timepoints

Participants answered a question at individual time points: "how much relief do you have from your starting pain?" on a 11-point PR-NRS. Scale ranged from 0=no relief to 10=complete relief. Higher score indicated improvement in pain.

Time frame:
0.25 hours, 0.5 hours, 0.75 hours, 1 hours, 1.25 hours, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, and 12 hours
Reported as:
Least squares mean · Units on a scale
Pain Relief (PAR) Scores at Individual Timepoints
Units on a scaleArm 1: PlaceboArm 2: Naproxen Sodium 440 mgArm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mgArm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mgArm 5: Hydrocodone 10 mg + Acetaminophen 650 mg
0.25 hours0.45 ± 0.260.80 ± 0.181.36 ± 0.201.07 ± 0.191.04 ± 0.20
0.5 Hours0.51 ± 0.442.27 ± 0.313.46 ± 0.334.03 ± 0.333.23 ± 0.36
0.75 Hours0.77 ± 0.484.11 ± 0.355.10 ± 0.375.71 ± 0.365.08 ± 0.36
1 Hours1.06 ± 0.495.29 ± 0.355.91 ± 0.386.60 ± 0.376.03 ± 0.37
1.25 Hours1.13 ± 0.495.99 ± 0.356.46 ± 0.387.17 ± 0.376.40 ± 0.37
1.5 Hours1.18 ± 0.486.36 ± 0.346.89 ± 0.377.65 ± 0.366.44 ± 0.36
2 Hours1.08 ± 0.486.62 ± 0.347.37 ± 0.377.97 ± 0.366.38 ± 0.36
3 Hours1.37 ± 0.496.52 ± 0.357.61 ± 0.388.24 ± 0.376.26 ± 0.37
4 Hours1.66 ± 0.511.46 ± 0.367.68 ± 0.398.46 ± 0.385.96 ± 0.38
5 Hours1.59 ± 0.526.45 ± 0.377.43 ± 0.408.23 ± 0.395.54 ± 0.40
6 Hours1.53 ± 0.536.26 ± 0.387.23 ± 0.418.15 ± 0.404.88 ± 0.40
7 Hours1.51 ± 0.556.05 ± 0.396.80 ± 0.427.94 ± 0.414.50 ± 0.41
8 Hours1.65 ± 0.545.95 ± 0.396.63 ± 0.427.71 ± 0.414.23 ± 0.41
9 Hours1.61 ± 0.565.73 ± 0.406.27 ± 0.437.44 ± 0.423.88 ± 0.43
10 Hours1.73 ± 0.585.71 ± 0.425.66 ± 0.457.49 ± 0.443.66 ± 0.44
11 Hours1.86 ± 0.605.71 ± 0.435.33 ± 0.467.26 ± 0.453.91 ± 0.46
12 Hours1.89 ± 0.615.62 ± 0.445.18 ± 0.477.25 ± 0.463.98 ± 0.46
SecondaryPain Intensity Difference (PID) Scores at Individual Time Points

Pain Intensity was self-reported over 12 hours, using a pain rating of 0-10 on the PI-NRS, with score ranged from 0-10 (0= no pain; 10 = worst imaginable pain). Pain intensity differences were calculated with respect to baseline at each time point after study drug administration.

Time frame:
0.25 hours, 0.5 hours, 0.75 hours, 1 hours, 1.25 hours, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, and 12 hours
Reported as:
Least squares mean · Units on a scale
Pain Intensity Difference (PID) Scores at Individual Time Points
Units on a scaleArm 1: PlaceboArm 2: Naproxen Sodium 440 mgArm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mgArm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mgArm 5: Hydrocodone 10 mg + Acetaminophen 650 mg
0.25 hours0.25 ± 0.210.58 ± 0.151.01 ± 0.160.85 ± 0.1500.79 ± 0.16
0.5 Hours0.07 ± 0.331.82 ± 0.242.61 ± 0.253.06 ± 0.252.36 ± 0.25
0.75 Hours0.24 ± 0.383.15 ± 0.273.82 ± 0.294.31 ± 0.293.77 ± 0.29
1 Hours0.45 ± 0.393.97 ± 0.284.41 ± 0.304.95 ± 0.294.48 ± 0.30
1.25 Hours0.34 ± 0.404.50 ± 0.284.87 ± 0.305.42 ± 0.304.71 ± 0.30
1.5 Hours0.31 ± 0.394.72 ± 0.285.18 ± 0.305.76 ± 0.294.74 ± 0.30
2 Hours0.22 ± 0.404.87 ± 0.285.49 ± 0.316.01 ± 0.304.67 ± 0.30
3 Hours0.34 ± 0.414.75 ± 0.305.62 ± 0.326.17 ± 0.314.51 ± 0.31
4 Hours0.53 ± 0.434.63 ± 0.315.64 ± 0.336.31 ± 0.324.26 ± 0.33
5 Hours0.50 ± 0.444.59 ± 0.325.51 ± 0.346.13 ± 0.333.89 ± 0.34
6 Hours0.47 ± 0.444.50 ± 0.325.28 ± 0.346.06 ± 0.333.39 ± 0.34
7 Hours0.40 ± 0.454.36 ± 0.324.96 ± 0.345.82 ± 0.343.08 ± 0.34
8 Hours0.48 ± 0.454.17 ± 0.324.74 ± 0.345.68 ± 0.342.90 ± 0.34
9 Hours0.53 ± 0.464.04 ± 0.334.46 ± 0.355.41 ± 0.342.56 ± 0.35
10 Hours0.64 ± 0.404.01 ± 0.353.87 ± 0.375.43 ± 0.362.42 ± 0.37
11 Hours0.69 ± 0.503.99 ± 0.353.63 ± 0.385.16 ± 0.372.71 ± 0.37
12 Hours0.71 ± 0.503.91 ± 0.363.53 ± 0.385.16 ± 0.372.66 ± 0.38
SecondaryParticipant's Global Evaluation of Study Medication OR Overall Impression of Study Medication According to Participant's Global Evaluation

Participants were asked to rate their overall impression of the study medication using the following scale: poor (0), fair (1), good (2), very good (3), and excellent (4) where higher score represented better outcome.

Time frame:
Up to 12 hours
Reported as:
Least squares mean · Units on a Scale
Participant's Global Evaluation of Study Medication OR Overall Impression of Study Medication According to Participant's Global Evaluation
Units on a ScaleArm 1: PlaceboArm 2: Naproxen Sodium 440 mgArm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mgArm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mgArm 5: Hydrocodone 10 mg + Acetaminophen 650 mg
Participant's Global Evaluation of Study Medication OR Overall Impression of Study Medication According to Participant's Global Evaluation0.8 ± 0.182.7 ± 0.132.9 ± 0.143.3 ± 0.132.7 ± 0.14

Adverse events

Collected over Up to Day 10. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: Placebo0/35 (0%)0/35 (0%)14/35 (40%)
Arm 2: Naproxen Sodium 440 mg0/69 (0%)0/69 (0%)5/69 (7.2%)
Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg0/61 (0%)0/61 (0%)8/61 (13.1%)
Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg0/63 (0%)0/63 (0%)9/63 (14.3%)
Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg0/62 (0%)0/62 (0%)22/62 (35.5%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventArm 1: PlaceboArm 2: Naproxen Sodium 440 mgArm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mgArm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mgArm 5: Hydrocodone 10 mg + Acetaminophen 650 mg
NauseaGastrointestinal disorders9/352/692/613/6320/62
VomitingGastrointestinal disorders7/352/694/616/639/62
HeadacheNervous system disorders4/350/690/610/631/62
Alveolar osteitisInfections and infestations0/351/693/611/630/62
DizzinessNervous system disorders0/352/691/611/633/62
Upper respiratory tract infectionInfections and infestations1/350/692/611/630/62
DiarrhoeaGastrointestinal disorders1/350/690/610/630/62
Gastrooesophageal reflux diseaseGastrointestinal disorders1/350/690/610/630/62
Postoperative wound infectionInfections and infestations0/350/690/611/631/62
InfluenzaInfections and infestations0/351/690/610/630/62

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm 1: PlaceboArm 2: Naproxen Sodium 440 mgArm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mgArm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mgArm 5: Hydrocodone 10 mg + Acetaminophen 650 mgTotal
Mean18.4 ± 1.5019.0 ± 2.3918.2 ± 1.3319.0 ± 2.2318.3 ± 1.7018.6 ± 1.95
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: PlaceboArm 2: Naproxen Sodium 440 mgArm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mgArm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mgArm 5: Hydrocodone 10 mg + Acetaminophen 650 mgTotal
Female1936333532155
Male1633282830135
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1: PlaceboArm 2: Naproxen Sodium 440 mgArm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mgArm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mgArm 5: Hydrocodone 10 mg + Acetaminophen 650 mgTotal
Hispanic or Latino8956634
Not Hispanic or Latino2760565756256
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1: PlaceboArm 2: Naproxen Sodium 440 mgArm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mgArm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mgArm 5: Hydrocodone 10 mg + Acetaminophen 650 mgTotal
American Indian or Alaska Native110114
Asian0324110
Native Hawaiian or Other Pacific Islander022206
Black or African American110002
White3261575457261
More than one race000000
Unknown or Not Reported110237
08

Study locations

1 site
  • Jean Brown Research Clinical Research
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Johnson \& Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.

Data sharing details ↗ · yoda.yale.edu

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Nov 2019, 5 months.

Results were first posted in Dec 2022, 3 years after primary completion. A results delay was requested in Nov 2020.

Of 62 industry-sponsored phase 2 interventional studies under Pain, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 5 months is below that.

Counting every sponsor, half of 186 studies reached it within 21 months; a quarter within 7 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2019
First posted
Mar 18, 2019
StartActual
May 28, 2019
Primary completionActual
Nov 7, 2019
CompletionActual
Nov 13, 2019
Results delay requested
Nov 3, 2020
Results first posted
Dec 5, 2022
Last update
Dec 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03879408
Responsible party
Sponsor
First posted
Mar 18, 2019
Start date
May 28, 2019
Primary completion
Nov 7, 2019
Completion
Nov 13, 2019
Results posted
Dec 5, 2022
Last update
Dec 5, 2022

Study contacts

Todd Bertoch, MD
principal investigator · Jean Brown Research (JBR)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naproxen · Acetaminophen

Start the discussion